We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Surrounding Cells Prevent Damage from ALS Mutant Gene

By Biotechdaily staff writers
Posted on 14 Oct 2003
Researchers working with a mouse model for amyotrophic lateral sclerosis (ALS) have found that surrounding neurons carrying the ALS mutant SOD1 gene with normal non-neuronal cells slows or prevents the onset of ALS symptoms.

Investigators at the University of California, San Diego (USA), genetically engineered a line of chimeric mice that carried the mutated gene of ALS in motor neurons but the normal gene in the surrounding non-neuronal tissue.

The study, which was published in the October 3, 2003, issue of Science, showed that even when as many as three-fourths of the motor neurons in the animals' spinal cords carried the mutant gene, all the motor neurons remained healthy, and survival of the animals was increased by one to eight months or more. More...
On the other hand, mice with normal motor neurons but with surrounding cells carrying an SOD1 mutation showed early signs of disease.

"What we have been given is a new principle for extending survival or, perhaps, overcoming ALS, based on how many healthy cells surround an ailing motor nerve cell,” explained senior author Dr. Don Cleveland, a researcher at the University of California, San Diego. "All this has great implications for stem cell therapy. We now believe delivery of normal, non-neuronal cells to spinal cords could be completely protective, even without replacement of a single motor neuron.”



Related Links:
University of California, San Diego

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.